研究目的
To compare visual field outcomes of ocular hypertensive and glaucoma patients treated with Medicine-1st against those treated with selective laser trabeculoplasty (SLT, Laser-1st).
研究成果
A slightly larger proportion of ocular hypertensive and glaucoma patients treated with Medicine-1st underwent rapid visual field progression compared with those treated with Laser-1st, suggesting that Laser-1st may delay visual field progression.
研究不足
The study did not monitor actual dose administration of eye drops, relying on self-reported concordance. The influence of cataract on the results was noted, with higher rates of cataract in the Medicine-1st group potentially affecting the outcomes.
1:Experimental Design and Method Selection:
The study used hierarchical linear models to estimate pointwise visual field progression rates, which were then averaged to produce a global progression estimate for each eye.
2:Sample Selection and Data Sources:
344 patients (588 eyes) treated with Medicine-1st and 344 patients (590 eyes) treated with Laser-1st from the LiGHT trial.
3:List of Experimental Equipment and Materials:
Humphrey Field Analyzer (HFA) with Swedish interactive threshold algorithm standard 24-2 programme.
4:Experimental Procedures and Operational Workflow:
Visual fields were measured and arranged in series (median length and duration: 9 VFs over 48 months).
5:Data Analysis Methods:
Log-binomial regression was used to compare the proportion of points and patients in each treatment group with fast or moderate progression.
独家科研数据包,助您复现前沿成果,加速创新突破
获取完整内容